Among 269,617 Medicare-age adults starting first-line hypertension treatment, those who began an angiotensin receptor blocker (ARB) had a 30% lower hazard of incident Parkinson's disease than those starting other first-line drugs (adjusted HR 0.70, 95% CI 0.59-0.83), and 19% lower than ACE inhibitor starters (aHR 0.81). Calcium channel blockers showed a weaker signal (aHR 0.88, 95% CI 0.77-0.99). Losartan and amlodipine surfaced independently in medication-wide screening of a biobank and replicated in separate cohorts. The ARB association shrank when the analysis imposed a 5-year outcome lag.
That attenuation is the crucial caveat. Early Parkinson's can involve years of silent prodromal change, including autonomic shifts that alter blood pressure and prescribing, so reverse causation or residual confounding could explain part of the effect. Target trial emulation reduces immortal-time and prevalent-user biases but cannot replace randomization, and claims data lack lifestyle, genetic and severity detail. The transcriptomic work, showing sacubitril/valsartan expression changes opposing Parkinson's signatures, is hypothesis-generating only. Brain-penetrant ARBs have drawn interest before through neuroinflammation and dopaminergic-neuron protection, and earlier observational findings were inconsistent, so this is a sizable, methodologically careful addition rather than a settled answer. This work is a preprint that has not been peer reviewed, and estimates may shift. Practically, no one should switch or start a blood-pressure drug to prevent Parkinson's. Choose agents for blood-pressure control and cardiovascular protection; if ARBs prove neuroprotective, that would be a bonus. A randomized trial would be needed to test it. Overall: incremental but encouraging.